CD27 and COVID-19: The activated CD27+CD21– subset of MBCs has recently been noted to remain expanded in some resolved COVID-19 patients (51), consistent with emerging literature supporting the possibility of prolonged antigen persistence, exemplified by a recent study detecting SARS-CoV-2 in the small bowel 4 months after asymptomatic infection (9).